GERD and H. pylori: Does it matter?

Practical Gastroenterology

Volumn 25, Issue 7, 2001, Pages

  Falk, G W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CAGA PROTEIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; VACUOLATING TOXIN; VIRULENCE FACTOR;

ATROPHIC GASTRITIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LONG TERM CARE; PATHOGENESIS; PEPTIC ULCER; REVIEW; TREATMENT OUTCOME;

EID: 0034898049     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management
2. Opposing time trends of peptic ulcer and reflux disease
3. Decreased prevalence of H. pylori infection in gastroesophageal reflux disease
4. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis
5. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: A study from the East
6. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: Case control study in Japan
7. Curing Helicobacter pylori infection in patients with duodenal ulcer disease may provoke reflux esophagitis
8. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection
9. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy
10. Corpus gastritis is protective against reflux oesophagitis
11. Helicobacter pylori infection and chronic gastric acid hyposecretion
12. CagA, the cag pathogenicity island and Helicobacter pylori infection
13. The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
14. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
15. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report
16. Lack of effect of acid suppression therapy on gastric atrophy
17. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa
18. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
19. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status
20. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole